[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurodegenerative-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurodegenerative-disorders":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,80,116,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100583561","elemental-028-extra-case-studies-100583561",false,"NCT06877923","Elemental 028 Extra Case Studies","Evaluating the Tolerance, Compliance and Acceptability of a Nutritionally Complete Amino Acid-based Nutritional Supplement for the Dietary Management of Conditions With a Severe Impairment of the Gastrointestinal Tract in Children and Adults: a Case Study Series","E028E","Inclusion Criteria:\n\n* Male or female\n* Over 3 years of age\n* Requiring an elemental feed (at least 30% of total energy requirements)\n* Written or electronic informed consent from patient, and\u002For from parent\u002Fcaregiver if applicable\n\nExclusion Criteria:\n\n* Pregnant or lactating\n* Requiring parenteral nutrition\n* Major hepatic or renal dysfunction\n* Participation in other studies within 1 month prior to entry of this study\n* Investigator concern around willingness\u002Fability of patient or parent\u002Fcaregiver to comply with protocol requirements","ALL","3 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","Elemental 028 Extra is a nutritionally complete ACBS approved amino acid-based (elemental) feed designed to provide adequate daily amounts of both macronutrients and micronutrients when used as a sole source of nutrition and to support patients with severe impairment of the gastrointestinal tract who may require an elemental diet. An upgraded formulation of Elemental 028 Extra with an increased energy, protein content micronutrient profile has been developed to better meet the nutritional requirements of patients.\n\nThis series of case-studies aims to evaluate the acceptability, compliance, and gastrointestinal tolerance of the upgraded formulation of Elemental 028 Extra, in 30 adult and paediatric patients (15 powder and 15 liquid), with conditions where there is a severe impairment of the gastrointestinal tract, such as inflammatory bowel disease, short bowel syndrome, intractable malabsorption, allergic disease, and neurodegenerative diseases, and an elemental feed is required. The case study will last 29 days in total, including a 1-day baseline period followed by a 28-day intervention period. The case studies will be conducted across multiple centres in the UK, to meet the UK ACBS and GMS requirements for acceptability studies.",[27,28,29,30,31,32],"Gastrointestinal Disease","Inflammatory Bowel Disease (IBD)","Short Bowel","Malabsorption","Allergies","Neurodegenerative Disorders","RECRUITING","2026-02-13",{"date":36,"type":37},"2026-02-17","ACTUAL",{"date":39,"type":37},"2025-05-01",{"date":41,"type":21},"2027-02",{"name":43,"class":44},"Nutricia UK Ltd","INDUSTRY",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":45},"100609908","effects-of-sabroxy-supplementation-on-insulin-resistance-and-cognitive-function-in-adults-with-mild-cognitive-impairment-and-insulin-resistance-100609908","NCT07220694","Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairment and Insulin Resistance","An 8-week Study Evaluating the Effects of a Dietary Supplement (Sabroxy®) on Insulin Resistance and Cognitive Function in Subjects With Mild Cognitive Impairment and Insulin Resistance","Inclusion Criteria:\n\n1. Female or male, adults grouped by age as follows 2 groups of 70 patients each (35 active and 35 placebo )\n\n   * GROUP 1 = aged 40 - 60, and\n   * GROUP 2 = aged 61 - 80\n2. In good general health\n3. Screening HOMA-IR value ≥ 2.0 to \\\u003C 4.0\n4. Screening fasting glucose 100 to 135 mg\u002FdL\n5. Screening MoCA less than 26\n\nExclusion Criteria:\n\n1. Having been diagnosed with known allergies to any ingredients in the study product.\n2. Relevant history or presence of any medical disorder potentially interfering with this study (e.g., malabsorption, chronic gastrointestinal diseases, severe depression, cardiovascular disease occurrence within the last 3 months, etc.),\n3. Regular intake of medications or supplements known to affect glucose tolerance\n4. Breastfeeding, pregnant, or planning to become pregnant during the study, according to the subject's self-report.\n5. Having a pregnant partner or a partner who is planning to become pregnant during the study period or is unwilling or unable to use an acceptable method of contraception.\n6. Having a history of skin cancer within the past 5 years.\n7. Having a history of immunosuppression\u002Fimmune deficiency disorders (including HIV infection, it has been AIDS, multiple sclerosis, Crohn's disease, rheumatoid arthritis), organ transplant (heart, kidney, etc.), or currently using oral or systemic immunosuppressive medications and biologics (e.g., azathioprine, belimumab, Cimzia®, Cosentyx®, cyclophosphamide, cyclosporine, Enbrel®, Humira®, Imuran®, Kineret®, mycophenolate mofetil, methotrexate, Orencia®, prednisone, Remicade®, Rituxan®, Siliq™, Simponi®, Stelara®, Taltz®) and\u002For undergoing radiation or chemotherapy as determined by study documentation.\n8. Currently using or having regularly used corticosteroids (systemic or topical, not nasal or ocular) within the past 4 weeks (including but not limited to betamethasone, clobetasol, desoximetasone, diflorasone, fluocinonide, halcinonide, and halobetasol).\n9. Having a disease such as asthma, diabetes, epilepsy, hypertension, hyperthyroidism, or hypothyroidism that is not controlled by diet or medication. Individuals having multiple health conditions may be excluded from participation even if the conditions are controlled by diet, medication, etc.\n10. Having started a long-term medication within the last 2 months.\n11. Having planned surgeries or invasive medical procedures during the study. Non-invasive medical procedures or surgeries will be reviewed for their impact on the study outcome and acceptability by the Investigator or designee.\n12. Currently participating in any other clinical trial at SFRI or another research facility or doctor's office.\n13. Having participated in any other clinical trial that evaluates or applies interventions to the same body system, organ, or condition being studied in this trial within 12 weeks prior to the screening visit at SFRI or another research facility or doctor's office.\n14. Note - Medications for treatment of chronic diseases that do not affect the metabolism of the study product will be permitted and will be judged individually regarding interference with the study by an investigator.",true,"40 Years","80 Years",{"count":57,"type":21},140,[24],"This randomized, double-blind, placebo-controlled, 8-week clinical trial is designed to evaluate the effects of Sabroxy®, a standardized extract of Oroxylum indicum bark, on insulin resistance and cognitive function in adults with mild cognitive impairment and insulin resistance.\n\nA total of 120 participants (men and women, aged 40-80 years) who are non-smokers, with fasting glucose levels between 100-135 mg\u002FdL, HOMA-IR value ≥ 2.0 to \\\u003C 4.0, and a Montreal Cognitive Assessment (MoCA) score below 26, will be enrolled. Eligible participants will be randomized (1:1) to receive either Sabroxy® (250 mg with 5 mg BioPerine®) or placebo, administered orally once daily for 8 weeks.\n\nThe primary endpoint is the change in insulin resistance from baseline to Week 8, assessed using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).\n\nThe secondary endpoints include changes in:\n\nCognitive performance, assessed using the Immediate Word Recall, Numeric Working Memory, Cognitive Failures Questionnaire (CFQ), and Montreal Cognitive Assessment (MoCA).\n\nBiomarkers of metabolic and neuronal function, including Brain-Derived Neurotrophic Factor (BDNF), high-sensitivity C-reactive protein (hs-CRP), fasting insulin, fasting glucose, and phosphorylated tau\u002Famyloid beta (p-Tau\u002FAβ) ratio.\n\nSafety will be assessed through adverse event monitoring, vital signs, and routine clinical laboratory tests.\n\nThe study will be conducted at a single site, San Francisco Research Institute (USA), in compliance with the Declaration of Helsinki, ICH-GCP guidelines, and 21 CFR Part 312 (where applicable).\n\nThis study seeks to generate clinical evidence supporting the potential of Sabroxy® supplementation to improve glucose tolerance, reduce inflammation, and enhance cognitive function in individuals with early metabolic and neurocognitive dysfunctions.",[61,62,63,32],"Insulin Resistance","Mild Cognitive Impairment","Cognitive Decline",[65,66,67,68,69],"BioPerine","Insulin Sensitivity","Cognitive Function","Memory Performance","Sabroxy","2026-01-26",{"date":72,"type":37},"2026-01-28",{"date":74,"type":21},"2026-01-29",{"date":76,"type":21},"2026-04-29",{"name":78,"class":79},"SF Research Institute, Inc.","NETWORK",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":53,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":115},"100600602","optimization-of-adaptive-rowing-seating-100600602","NCT07099625","Optimization of Adaptive Rowing Seating","Optimization of Adaptive Rowing Seating (OARS)","OARS","Inclusion Criteria:\n\n* Non-ventilator dependent paralysis, such as:\n\n  * central nervous system impairment\n  * spinal cord injuries with single neurological level in the cervical to lumbosacral region\n  * cerebrovascular accident with associated sequelae including but not limited to hemiparesis and spasticity\n  * neurodegenerative disorders including but not limited to amyotrophic lateral sclerosis, multiple sclerosis, multiple system atrophy, and parkinsonism\n* Poor trunk control\u002Fstability\n* Ability of body structure to fit within the limits of AIRS and the rowing system\n* Either volitional control of lower extremities or response\u002Ftolerance to electrical stimulation\n* Individuals who would be classified as PR2 or PR1 - FISA Para-Rowing Classifications\n\nExclusion Criteria:\n\n* Veterans will be excluded if they have:\n\n  * acute illness or injury\n  * active or recent pressure injuries in the last 6 months affecting their ability to safely row (e.g., the coccyx, ischial tuberosity, sacrum, etc.)\n* Individuals who would be classified as NE or PR3-PD - FISA Para-Rowing Classifications\n* Flap procedure to address pressure injury less than one year prior\n* Upper extremity pain that restricts rowing\n* Surgical procedure within past 6 months that would make the study procedures unsafe (e.g., tendon repairs\u002Ftransfers, neural decompressions, bony fusions, etc.)\n* Upper extremity or spine fractures within past 3 months, or longer if remains unstable\u002Fnot fully healed.\n* Medical conditions such as cardiovascular disease, pulmonary disease, or other conditions that would make the study procedures unsafe pregnancy\n* Inability to communicate with the study team in real time\n* Inability to follow simple commands\n* Unable or unwilling to give consent","18 Years",{"count":90,"type":21},15,[24],"Adaptive sports programs are integral components to combating Veteran isolation, promoting wellbeing and seeking to build teams, networks, communities. These activity-based communities are medicine free treatment systems enhancing Veterans' health from a holistic perspective. This approach to Veteran healthcare is critical as studies indicate Veterans not only have 56% higher perceived social isolation but are also 1.5x more susceptible to suicide than the general public. It is imperative to improve access to exercise and physical activity through adaptive sport or recreation. This proposal is going to focus on Adaptive Indoor Rowing for Veterans with limited or changing trunk stability (i.e. SCI\u002FD, paralysis, paresis, etc.). Rowing is a unique full-body activity that increases cardiovascular demand and increases coordination and aerobic capacity through movement. This proposal aims to address critical gaps in adaptive rowing technology and provide Veterans with limited trunk stability access to full stroke adaptive rowing.",[94,95,32,96],"Spinal Cord Diseases","Spinal Cord Injuries","Cerebrovascular Accident With Associated Sequelae",[98,99,100,101,102,103],"Veteran Health","Sports for Persons with Disabilities","Paralysis","Paresis","Adaptive Sports","Indoor Rowing","NOT_YET_RECRUITING","2025-07-25",{"date":107,"type":37},"2025-08-01",{"date":109,"type":21},"2026-07-06",{"date":111,"type":21},"2028-09-30",{"name":113,"class":114},"VA Office of Research and Development","FED",2,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":53,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":126,"conditions":127,"keywords":128,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":45},"100123502","development-of-ips-from-donated-somatic-cells-of-patients-with-neurological-diseases-100123502","NCT00874783","Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases","Derivation of Induced Pluripotent Stem Cells from Somatic Cells Donated by Patients with Neurological Diseases for the Study of the Pathogenesis of the Disorders and Development of Novel Therapies","Inclusion Criteria:\n\n* Donors suffering from different (specified) neurodegenerative disorders scheduled to undergo surgery for medical reasons or will donate a single or a few hairs--to be removed intact from the scull or other areas in the body.\n* Healthy donors scheduled to undergo surgery for medical reasons or will donate a single or a few hairs--to be removed intact from the scull or other areas in the body.\n\nExclusion Criteria:\n\n* None",{"count":124,"type":21},120,"OBSERVATIONAL","Human fibroblasts and possibly other human somatic cells may be reprogrammed into induced pluripotent stem (iPS) cells by the forced expression of transcription factors (1-5). The iPS cells seem to share many properties with human embryonic stem cells.\n\nInduced pluripotent stem cells potentially may be useful in the future as an unlimited source of cells for transplantation.\n\nThe major goal of the project is to develop human iPS cells from cell cultures from skin biopsies or the patient's hair. The iPS cells will be developed primarily for modeling diseases and drug discovery as well as basic research, and for developing the technology that may eventually allow the use of iPS cells for future transplantation therapy. The iPS cells developed in the course of this application are not intended for use in transplantation therapy. Future development of iPS cells for clinical transplantation therapies will be subjected to the appropriate authorization by ethical and regulatory committees.",[32],[129,130,131,132,133,134,135,136,137,138],"Amyotrophic Lateral Sclerosis","Familial Dysautonomia","Parkinson's Disease","Alzheimer's Disease","Age Related Macular Degeneration","Retinitis Pigmentosa","Huntington's Disease","Machado - Joseph Disease","SMA - Spinal Muscular Atrophy","Ataxia Telangiectasia","2025-03-03",{"date":141,"type":37},"2025-03-04",{"date":143,"type":37},"2009-04",{"date":145,"type":21},"2030-12",{"name":147,"class":148},"Hadassah Medical Organization","OTHER",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":53,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":161,"conditions":162,"keywords":173,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":45},"100415052","phase-1-mesenchymal-stem-cells-for-the-treatment-of-various-chronic-and-acute-conditions-100415052","NCT04684602","Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions","Evaluation of the Safety, Tolerability and Efficacy of Regenerative Therapy for the Treatment of Various Chronic and Acute Conditions","Inclusion Criteria:\n\n* Age 18 and older\n* Ability to provide informed consent\n* Availability for follow up visits\n\nExclusion Criteria:\n\n* Active or recent malignancy (within last 2 years)\n* Pregnancy or breast-feeding\n* Inability to provide informed consent",{"count":157,"type":21},5000,[159,160],"PHASE1","PHASE2","This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions. Clinically observed initial findings and an extensive body of research indicate regenerative treatments are both safe and effective for the treatment of multiple conditions.",[163,164,165,166,167,32,168,169,170,171,172],"Autoimmune Diseases","Cardiovascular Disorders","Diabetes Complications","Integumentary Disease","Musculoskeletal Disorders","Neurologic Disorders","Pulmonary Disorders","Sexual Dysfunction","Urologic Disorders","Viral Illness",[174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200],"stem cell therapy","umbilical cord stem cells","amniotic stem cells","stem cells","MSC","Mesenchymal Stem Cell","Medicinal Signaling Cell","Erectile Dysfunction","Heart Diseases","Mental Disorders","Neurocognitive Disorders","Neurodegenerative Diseases","Central Nervous System Diseases","Tauopathies","Brain Diseases","Dementia","Disease","Cardiomyopathies","Urologic Diseases","Peripheral Nervous System Diseases","Nervous System Diseases","Alzheimer Disease","Musculoskeletal Diseases","Cardiovascular Diseases","Immune System Diseases","Neuromuscular Diseases","Covid-19","2022-04-27",{"date":203,"type":37},"2022-04-29",{"date":205,"type":37},"2020-07-09",{"date":207,"type":21},"2030-12-09",{"name":209,"class":44},"Thomas Advanced Medical LLC"]